DK1697326T3 - Krystalform af en quinolinforbindelse og fremgangsmåde til fremstilling deraf - Google Patents
Krystalform af en quinolinforbindelse og fremgangsmåde til fremstilling derafInfo
- Publication number
- DK1697326T3 DK1697326T3 DK04807807.5T DK04807807T DK1697326T3 DK 1697326 T3 DK1697326 T3 DK 1697326T3 DK 04807807 T DK04807807 T DK 04807807T DK 1697326 T3 DK1697326 T3 DK 1697326T3
- Authority
- DK
- Denmark
- Prior art keywords
- crystal form
- preparation
- quinoline compound
- stability
- drug substance
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003431788 | 2003-12-26 | ||
PCT/JP2004/019451 WO2005063711A1 (en) | 2003-12-26 | 2004-12-17 | Crystal form of quinoline compound and process for its production |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1697326T3 true DK1697326T3 (da) | 2011-09-19 |
Family
ID=34736450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04807807.5T DK1697326T3 (da) | 2003-12-26 | 2004-12-17 | Krystalform af en quinolinforbindelse og fremgangsmåde til fremstilling deraf |
Country Status (22)
Country | Link |
---|---|
US (19) | US20070112024A1 (da) |
EP (1) | EP1697326B1 (da) |
JP (7) | JP5186108B2 (da) |
KR (11) | KR20170098976A (da) |
CN (2) | CN1898211A (da) |
AT (1) | ATE518835T1 (da) |
AU (2) | AU2004309241A1 (da) |
CA (1) | CA2551050C (da) |
CY (1) | CY1112464T1 (da) |
DK (1) | DK1697326T3 (da) |
ES (1) | ES2367172T3 (da) |
HK (1) | HK1095328A1 (da) |
IL (1) | IL176470A (da) |
MX (1) | MX338019B (da) |
NZ (1) | NZ548041A (da) |
PL (1) | PL1697326T3 (da) |
PT (1) | PT1697326E (da) |
RU (1) | RU2370489C2 (da) |
SI (1) | SI1697326T1 (da) |
TW (1) | TWI328006B (da) |
WO (1) | WO2005063711A1 (da) |
ZA (1) | ZA200605658B (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004072040A1 (en) | 2003-02-12 | 2004-08-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of pitavastatin calcium |
TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
US7801272B2 (en) * | 2007-09-28 | 2010-09-21 | Rigaku Corporation | X-ray diffraction apparatus and X-ray diffraction method |
WO2011089623A2 (en) * | 2010-01-20 | 2011-07-28 | Cadila Healthcare Limited | Process for preparing pitavastatin and pharmaceutically acceptable salts thereof |
KR101158517B1 (ko) | 2010-04-29 | 2012-06-21 | 동방에프티엘(주) | 고 순도 피타바스타틴 칼슘염 결정형 a의 제조방법 |
WO2012025939A1 (en) | 2010-08-25 | 2012-03-01 | Cadila Healthcare Limited | Pitavastatin calcium and process for its preparation |
EP3178812A1 (en) | 2010-11-12 | 2017-06-14 | Hetero Research Foundation | Novel polymorphs of pitavastatin calcium |
RU2452939C1 (ru) * | 2011-01-18 | 2012-06-10 | Закрытое акционерное общество "Научные приборы" | Рентгенодифракционный способ идентификации партий фармацевтической продукции |
ITMI20111475A1 (it) * | 2011-08-02 | 2013-02-03 | Dipharma Francis Srl | Forme cristalline di pitavastatina sale di calcio |
EP2751081B1 (en) | 2011-09-12 | 2017-01-04 | Farma GRS, d.o.o. | Polymorphic form of pitavastatin calcium |
WO2013098773A1 (en) * | 2011-12-28 | 2013-07-04 | Dr. Reddy's Laboratories Limited | Crystalline forms of pitavastatin calcium |
EP3124017A1 (en) | 2012-08-08 | 2017-02-01 | Kowa Company, Ltd. | Pharmaceutical composition comprising pitavastatine |
US9464095B2 (en) * | 2012-09-27 | 2016-10-11 | Nissan Chemical Industries, Ltd. | Production method of high-purity nitrogen-containing heterocyclic compound |
JP2014034574A (ja) * | 2013-01-25 | 2014-02-24 | Kowa Company Ltd | 医薬 |
CN105228984B (zh) * | 2013-03-15 | 2018-03-23 | 爱西里斯药物技术有限公司 | 硝羟喹啉碱加成盐及其用途 |
CN105213319A (zh) * | 2015-09-17 | 2016-01-06 | 青岛华之草医药科技有限公司 | 一种降血脂药物匹伐他汀钙组合物干混悬剂 |
JP2016222714A (ja) * | 2016-09-20 | 2016-12-28 | 興和株式会社 | 医薬 |
TW202200547A (zh) * | 2020-03-13 | 2022-01-01 | 印度商卡地拉保健有限公司 | 喹啉酮化合物的新穎鹽類 |
CN116997331A (zh) * | 2021-03-19 | 2023-11-03 | 兹杜斯生命科学有限公司 | 固体形式的喹诺酮化合物及其制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3175944A (en) * | 1956-06-18 | 1965-03-30 | Upjohn Co | Dihydronovobiocin and derivatives thereof |
IL63968A (en) | 1980-10-01 | 1985-10-31 | Glaxo Group Ltd | Form 2 ranitidine hydrochloride,its preparation and pharmaceutical compositions containing it |
GB8320521D0 (en) * | 1983-07-29 | 1983-09-01 | Glaxo Group Ltd | Chemical process |
JPS61171460A (ja) * | 1985-01-23 | 1986-08-02 | Dainippon Pharmaceut Co Ltd | 塩酸メクロフエノキサ−ト1型結晶の製造法 |
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
JP2877366B2 (ja) | 1988-08-25 | 1999-03-31 | 協和醗酵工業株式会社 | 結晶状l−アスコルビン酸−2−リン酸ナトリウム塩の製造法 |
JP3528186B2 (ja) * | 1991-06-24 | 2004-05-17 | 日産化学工業株式会社 | 光学活性キノリンメバロン酸のジアステレオマー塩 |
JPH0613526A (ja) | 1992-06-25 | 1994-01-21 | Seiko Epson Corp | 半導体装置用リードフレーム及びその製造方法 |
JP2575590B2 (ja) * | 1992-07-31 | 1997-01-29 | 塩野義製薬株式会社 | トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法 |
FR2694558B1 (fr) | 1992-08-05 | 1994-10-28 | Sanofi Elf | Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant. |
DE4235133A1 (de) | 1992-10-19 | 1994-04-21 | Bayer Ag | Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid |
JP3623531B2 (ja) | 1993-06-07 | 2005-02-23 | ビーエーエスエフ アクチェンゲゼルシャフト | 結晶質l−アスコルビン酸−2−燐酸エステルマグネシウム塩の製造法 |
JP3558684B2 (ja) * | 1994-06-28 | 2004-08-25 | 塩野義製薬株式会社 | ピロリジルチオカルバペネム誘導体の乾燥方法 |
TR200302281T2 (tr) * | 2001-08-16 | 2004-09-21 | Teva Pharmaceutical Industries Ltd. | Statinlerin kalsiyum tuzu formlarını hazırlamak için işlemler |
US6835838B2 (en) | 2002-01-28 | 2004-12-28 | Novartis Ag | Process for the manufacture of organic compounds |
JP4524111B2 (ja) * | 2002-01-31 | 2010-08-11 | ノバルティス アーゲー | HMG−CoA還元酵素阻害剤の製造法 |
US6869970B2 (en) * | 2002-02-04 | 2005-03-22 | Novartis Ag | Crystalline salt forms of valsartan |
WO2003087091A1 (fr) * | 2002-04-17 | 2003-10-23 | Yamanouchi Pharmaceutical Co., Ltd. | Nouveau cristal d'anhydride de derive de quinoxalinedione |
WO2004072040A1 (en) * | 2003-02-12 | 2004-08-26 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of pitavastatin calcium |
TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
-
2004
- 2004-11-29 TW TW093136780A patent/TWI328006B/zh not_active IP Right Cessation
- 2004-12-17 WO PCT/JP2004/019451 patent/WO2005063711A1/en active Application Filing
- 2004-12-17 KR KR1020177023135A patent/KR20170098976A/ko not_active Application Discontinuation
- 2004-12-17 RU RU2006127044/04A patent/RU2370489C2/ru not_active Application Discontinuation
- 2004-12-17 JP JP2006520594A patent/JP5186108B2/ja active Active
- 2004-12-17 MX MX2011007418A patent/MX338019B/es unknown
- 2004-12-17 KR KR1020207003201A patent/KR20200015826A/ko active Application Filing
- 2004-12-17 PT PT04807807T patent/PT1697326E/pt unknown
- 2004-12-17 EP EP04807807A patent/EP1697326B1/en active Active
- 2004-12-17 NZ NZ548041A patent/NZ548041A/en unknown
- 2004-12-17 KR KR1020197019411A patent/KR20190083674A/ko not_active Application Discontinuation
- 2004-12-17 KR KR1020067011877A patent/KR20070001910A/ko not_active Application Discontinuation
- 2004-12-17 DK DK04807807.5T patent/DK1697326T3/da active
- 2004-12-17 KR KR1020117002847A patent/KR20110017936A/ko not_active Application Discontinuation
- 2004-12-17 KR KR1020187035028A patent/KR20180132973A/ko not_active Application Discontinuation
- 2004-12-17 CN CNA2004800389550A patent/CN1898211A/zh active Pending
- 2004-12-17 ES ES04807807T patent/ES2367172T3/es active Active
- 2004-12-17 AT AT04807807T patent/ATE518835T1/de active
- 2004-12-17 KR KR1020167016139A patent/KR20160075844A/ko not_active Application Discontinuation
- 2004-12-17 CA CA2551050A patent/CA2551050C/en active Active
- 2004-12-17 KR KR1020177001565A patent/KR20170010111A/ko not_active Application Discontinuation
- 2004-12-17 PL PL04807807T patent/PL1697326T3/pl unknown
- 2004-12-17 KR KR1020187010082A patent/KR20180040732A/ko not_active Application Discontinuation
- 2004-12-17 KR KR1020137001739A patent/KR20130014643A/ko not_active Application Discontinuation
- 2004-12-17 CN CN201110198613.7A patent/CN102321019B/zh active Active
- 2004-12-17 ZA ZA200605658A patent/ZA200605658B/en unknown
- 2004-12-17 US US10/584,208 patent/US20070112024A1/en not_active Abandoned
- 2004-12-17 SI SI200431760T patent/SI1697326T1/sl unknown
- 2004-12-17 KR KR1020207032499A patent/KR20200130510A/ko not_active Application Discontinuation
- 2004-12-17 AU AU2004309241A patent/AU2004309241A1/en not_active Abandoned
-
2006
- 2006-06-21 IL IL176470A patent/IL176470A/en active IP Right Grant
-
2007
- 2007-01-25 HK HK07100926.2A patent/HK1095328A1/xx unknown
-
2009
- 2009-03-11 US US12/401,945 patent/US20090176987A1/en not_active Abandoned
-
2010
- 2010-12-13 US US12/966,102 patent/US20110082298A1/en not_active Abandoned
-
2011
- 2011-08-18 AU AU2011213742A patent/AU2011213742C1/en active Active
- 2011-09-07 US US13/227,003 patent/US20110319624A1/en not_active Abandoned
- 2011-10-20 CY CY20111100995T patent/CY1112464T1/el unknown
- 2011-11-29 JP JP2011260984A patent/JP5267643B2/ja active Active
-
2012
- 2012-06-04 US US13/487,289 patent/US20120245200A1/en not_active Abandoned
-
2013
- 2013-03-15 US US13/832,285 patent/US20130204000A1/en not_active Abandoned
- 2013-04-05 JP JP2013079889A patent/JP2013136640A/ja not_active Withdrawn
- 2013-10-30 US US14/066,762 patent/US20140058109A1/en not_active Abandoned
-
2014
- 2014-03-21 US US14/221,372 patent/US20140206719A1/en not_active Abandoned
- 2014-08-01 JP JP2014157888A patent/JP2014205719A/ja not_active Withdrawn
-
2015
- 2015-02-18 US US14/625,046 patent/US20150158816A1/en not_active Abandoned
- 2015-11-16 JP JP2015224264A patent/JP2016029102A/ja not_active Withdrawn
-
2016
- 2016-09-15 US US15/266,095 patent/US20170226061A1/en not_active Abandoned
- 2016-11-22 JP JP2016227123A patent/JP2017061536A/ja not_active Withdrawn
-
2017
- 2017-11-15 US US15/813,422 patent/US20180072676A1/en not_active Abandoned
-
2018
- 2018-01-10 JP JP2018002103A patent/JP2018052988A/ja not_active Withdrawn
- 2018-06-19 US US16/011,870 patent/US20180297956A1/en not_active Abandoned
-
2019
- 2019-01-24 US US16/256,070 patent/US20190152916A1/en not_active Abandoned
- 2019-08-19 US US16/543,653 patent/US20190367458A1/en not_active Abandoned
-
2020
- 2020-03-16 US US16/819,317 patent/US20200216395A1/en not_active Abandoned
- 2020-11-05 US US17/090,353 patent/US20210053923A1/en not_active Abandoned
-
2022
- 2022-02-28 US US17/682,065 patent/US20220177433A1/en not_active Abandoned
-
2023
- 2023-06-14 US US18/334,683 patent/US20230322679A1/en not_active Abandoned
-
2024
- 2024-04-17 US US18/637,529 patent/US20240294476A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1095328A1 (en) | Crystal form of quinoline compound and process for its production | |
LU92300I2 (fr) | Regorafenib et ses sels pharmaceutiquement acceptables (STIVARGA) | |
CY1111327T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος | |
HRP20030079B1 (en) | Novel c-crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same | |
MXPA04004464A (es) | Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades. | |
AP1709A (en) | Ethanolate of azithromycin, process for manufacure, and pharmaceutical compositions thereof. | |
DK1877384T3 (da) | Fremgangsmåde til fremstilling af eventuelt 2-substituerede 1,6-dihydro-6-oxo-4-pyrimidincarboxylsyrer | |
PL1745010T3 (pl) | Podstawione pochodne cykloheksylo-1,4-diaminy | |
DK1373207T3 (da) | Nyt amlodipincamsylat og fremgangsmåde til fremstilling heraf | |
EA201990688A1 (ru) | Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение | |
TW200635905A (en) | Processes for producing 4-aminoquinazolines | |
NO20055694L (no) | Fremgangsmate for fremstilling av (4-hydroksy-6-oksotetrahydropyran-2-yl)acetonitril og derivater derav | |
HK1133001A1 (en) | Novel method for producing 4,4'-(1-methyl-1,2-ethanediyl)-bis-(2,6- piperazinedione) | |
NO20054418L (no) | Substituert benzoylureidopyridylpiperidin- og -pyrrolidinkarboksylsyrederivater, deres fremstilling og anvendelse | |
DE602004030616D1 (de) | Amlodipin-gentisat und verfahren zu dessen herstellung | |
DE602005013007D1 (de) | Verfahren zur herstellung von lactonen | |
DE60104103D1 (de) | Verfahren zur herstellung von hochkristallinem natrium cefoperazon | |
GB0417063D0 (en) | Process for the preparation of optically-active compounds | |
EA200600542A1 (ru) | Способ для производства thip | |
ATE533758T1 (de) | Verfahren zur herstellung von enantiomerenreinem esomeprazol | |
DK1513838T3 (da) | Teknisk fremgangsmåde til fremstilling af tropenol |